The 6 Most Shorted Nasdaq Stocks
As summer began to wind to a close, short selling perked up, at least among the most shorted stocks traded on the Nasdaq.
Headquartered in Queensbury, NY Fiscal year ends December NASDAQ: DCTH delcath.com
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Its proprietary products are designed to deliver high-dose chemotherapy directly to the liver through percutaneous hepatic perfusion (PHP) while controlling systemic exposure and associated side effects.
The products are:
- **HEPZATO KIT** (HEPZATO (melphalan) for Injection/Hepatic Delivery System): sold in the United States.
- **CHEMOSAT Hepatic Delivery System for Melphalan**: sold in Europe.
In the U.S., HEPZATO KIT is a drug-device combination product regulated and approved by the FDA as a drug, and it carries a boxed warning. It combines the chemotherapeutic melphalan with Delcath's Hepatic Delivery System (HDS). The HDS isolates hepatic venous blood from the systemic circulation and filters it during melphalan infusion and washout. HEPZATO KIT is approved for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver, with limited or resectable extrahepatic disease.
In Europe, the device-only HDS is regulated as a Class III medical device and sold as CHEMOSAT. It is used at major medical centers to treat a range of liver cancers.
The company generates revenue primarily from HEPZATO KIT sales to a network of U.S. treatment centers, currently 33 active centers. It is expanding into new indications:
- The global Phase 2 DELUMA trial in liver-dominant HER2-negative metastatic breast cancer.
- A planned IND for cholangiocarcinoma in early 2027.
- An oxaliplatin-based PHP product in preclinical development. Updated
As summer began to wind to a close, short selling perked up, at least among the most shorted stocks traded on the Nasdaq.
Short sellers shied away from the two most shorted stocks traded on the Nasdaq between the latest settlement dates, but they moved on other short seller favorites.
DryShips, Merrimack Pharma, Gevo, Delcath Systems post new 52-week lows Friday.
thinkstockHere are the five biggest gaining stocks in today’s U.S. markets at closing: Transition Therapeutics Inc. (NASDAQ: TTHI) is up 37.8% at $3.10. Digital Ally Inc. (NASDAQ: DGLY) is up 35.8% at…
U.S. equity markets opened mixed this morning as investors weighed conflicting data from the U.S., Europe, and Asia. In Europe, retail sales declined more than expected in Germany, Italy’s unemployment rate remained…
As the stock market keeps rising, investors have to expect that the wave of companies raising cash and insiders selling shares will only continue. We tracked a whopping 10 offerings yesterday alone…
ThinkstockLow-priced stocks can often have active volume already, and quite often due to perhaps nothing more than their low share price when news is announced. 24/7 Wall St. already tracked the active…
Photo by Spencer Platt/Getty ImagesThe stock market is mixed Monday, with the Dow Jones Industrial Average up 0.06%, the Nasdaq down 0.09% and the S&P 500 flat. Today’s big winner is a…
Stocks open slightly higher this morning, but quickly reversed course to begin falling in less than five minutes of trading. The DJIA hit a morning low just before noon and has bounced…
Heavy losses were sustained in three Tickerspy indexes over the last 30-day period. This month’s biggest index losers are in radio, Chinese advertising, and cancer treatment stocks. Radio stocks are down 15.2% in…
Today’s edition of the BioHealth Business Daily is going to be very cancer-dominated due to the American Society of Clinical Oncology (ASCO) 2010 meeting that started this last weekend. There are many…
There are almost too many key stocks to note as pre-market movers this morning because of the floodgates of earnings news. We have covered some of the larger volume and price movers…
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
The Wall Street consensus 12-month price target for DCTH is $28.60.